A clinical pharmacy specialist discusses what’s needed to get the REMS program set up and touches on reimbursement considerations for the administration of belantamab mafodotin in patients with multiple myeloma.
Kathryn Maples, PharmD, BCOP
Advertisement
Articles by Kathryn Maples, PharmD, BCOP
A clinical pharmacy specialist details her experience with the REMS program for administration of belantamab mafodotin in patients with multiple myeloma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA OKs Subcutaneous Daratumumab in High-Risk Smoldering Multiple Myeloma
2
How ADCs are Replacing Chemotherapy as Breast Cancer Treatment
3
Neoadjuvant Nivolumab/Ipilimumab Shows Superior EFS in Resectable Melanoma
4
What Were The Most Impactful GU Oncology Data From ESMO 2025?
5
